DM
Deerfield Management Portfolio holdings
AUM
$5.51B
1-Year Return
12.76%
This Quarter Return
+21.45%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.75B
AUM Growth
+$332M
(+6.1%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-14.52%
Top 10 Holdings %
Top 10 Hldgs %
51.71%
Holding
447
New
223
Increased
65
Reduced
45
Closed
77
Top Buys
| 1 |
BioNTech
BNTX
|
$52.5M |
| 2 |
Kyverna Therapeutics
KYTX
|
$36.3M |
| 3 |
Perspective Therapeutics
CATX
|
$33.5M |
| 4 |
Larimar Therapeutics
LRMR
|
$32.6M |
| 5 |
Surgery Partners
SGRY
|
$32.3M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
$66.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$64M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$62.6M |
| 4 |
Baxter International
BAX
|
$57.8M |
| 5 |
Neurocrine Biosciences
NBIX
|
$28.4M |
Sector Composition
| 1 | Healthcare | 88.87% |
| 2 | Industrials | 0.71% |
| 3 | Technology | 0.31% |
| 4 | Consumer Discretionary | 0.26% |
| 5 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Marvell Technology
MRVL
$54.5B
| $261K | ﹤0.01% |
3,687
-1,361
| -27% | -$96.5K |
|
277
Trinity Industries
TRN
$2.31B
| $260K | ﹤0.01% |
9,329
-2,492
| -21% | -$69.4K |
|
278
Stifel
SF
$11.5B
| $259K | ﹤0.01% |
+3,313
| New | +$259K |
|
279
Urban Edge Properties
UE
$2.66B
| $259K | ﹤0.01% |
+14,991
| New | +$259K |
|
280
Ecovyst
ECVT
$1.03B
| $259K | ﹤0.01% |
+23,217
| New | +$259K |
|
281
Mersana Therapeutics
MRSN
$34.3M
| $258K | ﹤0.01% |
+2,299
| New | +$258K |
|
282
Morgan Stanley
MS
$237B
| $257K | ﹤0.01% |
+2,734
| New | +$257K |
|
283
Progyny
PGNY
$1.92B
| $256K | ﹤0.01% |
+6,708
| New | +$256K |
|
284
Ecolab
ECL
$77.7B
| $256K | ﹤0.01% |
1,107
-95
| -8% | -$21.9K |
|
285
Dentsply Sirona
XRAY
$2.91B
| $255K | ﹤0.01% |
+7,690
| New | +$255K |
|
286
Cardinal Health
CAH
$35.6B
| $255K | ﹤0.01% |
+2,276
| New | +$255K |
|
287
America's Car Mart
CRMT
$299M
| $254K | ﹤0.01% |
+3,977
| New | +$254K |
|
288
Campbell Soup
CPB
$10B
| $253K | ﹤0.01% |
+5,701
| New | +$253K |
|
|
TOIIW
289
The Oncology Institute, Inc. Warrant
TOIIW
$9.91M
| $250K | ﹤0.01% |
1,250,000
| – | – |
|
290
Moderna
MRNA
$9.8B
| $249K | ﹤0.01% |
+2,337
| New | +$249K |
|
291
Alphabet (Google) Class A
GOOGL
$2.83T
| $248K | ﹤0.01% |
+1,644
| New | +$248K |
|
292
Visteon
VC
$3.42B
| $248K | ﹤0.01% |
2,108
-1,695
| -45% | -$199K |
|
293
NGL Energy Partners
NGL
$731M
| $247K | ﹤0.01% |
+42,830
| New | +$247K |
|
294
Nurix Therapeutics
NRIX
$761M
| $243K | ﹤0.01% |
16,517
+799
| +5% | +$11.7K |
|
295
UnitedHealth
UNH
$285B
| $242K | ﹤0.01% |
+490
| New | +$242K |
|
296
MasterBrand
MBC
$1.71B
| $240K | ﹤0.01% |
12,830
-9,772
| -43% | -$183K |
|
297
Fulgent Genetics
FLGT
$676M
| $238K | ﹤0.01% |
10,959
+1,130
| +11% | +$24.5K |
|
298
Mettler-Toledo International
MTD
$26.9B
| $236K | ﹤0.01% |
177
-61
| -26% | -$81.2K |
|
|
ENLC
299
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $236K | ﹤0.01% |
17,269
+6,594
| +62% | +$89.9K |
|
300
C4 Therapeutics
CCCC
$196M
| $234K | ﹤0.01% |
+28,590
| New | +$234K |
|